Cargando…
Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity
The avidity (binding strength) of IgG directed towards the receptor‐binding domain (RBD) of spike protein has been recognized as a central marker in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serology. It seems to be linked to increased infection‐neutralization potential and theref...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349558/ https://www.ncbi.nlm.nih.gov/pubmed/35851961 http://dx.doi.org/10.1002/jmv.28006 |
_version_ | 1784762130692571136 |
---|---|
author | Bauer, Georg Struck, Friedhelm Staschik, Eva Maile, Julia Wochinz‐Richter, Karin Motz, Manfred Soutschek, Erwin |
author_facet | Bauer, Georg Struck, Friedhelm Staschik, Eva Maile, Julia Wochinz‐Richter, Karin Motz, Manfred Soutschek, Erwin |
author_sort | Bauer, Georg |
collection | PubMed |
description | The avidity (binding strength) of IgG directed towards the receptor‐binding domain (RBD) of spike protein has been recognized as a central marker in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serology. It seems to be linked to increased infection‐neutralization potential and therefore might indicate protective immunity. Using a prototype line assay based on the established recomLine SARS‐CoV‐2 assay, supplemented with RBD of the delta and the omicron variant, differential avidity determination of IgG directed towards RBD of wild‐type (WT) SARS‐CoV‐2 and distinct variants was possible within one assay. Our data confirm that natural SARS‐CoV‐2 infection or one vaccination step lead to low avidity IgG, whereas further vaccination steps gradually increase avidity to high values. High avidity is not reached by infection alone. After infection with WT SARS‐CoV‐2 or vaccination based on mRNA WT, the avidity of cross‐reacting IgG directed towards RBD of the delta variant only showed marginal differences compared to IgG directed towards RBD WT. In contrast, the avidity of IgG cross‐reacting with RBD of the omicron variant was always much lower than for IgG RBD WT, except after the third vaccination step. Therefore, parallel avidity testing of RBD WT and omicron seems to be mandatory for a significant assessment of protective immunity towards SARS‐CoV‐2. |
format | Online Article Text |
id | pubmed-9349558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93495582022-08-04 Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity Bauer, Georg Struck, Friedhelm Staschik, Eva Maile, Julia Wochinz‐Richter, Karin Motz, Manfred Soutschek, Erwin J Med Virol Research Articles The avidity (binding strength) of IgG directed towards the receptor‐binding domain (RBD) of spike protein has been recognized as a central marker in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) serology. It seems to be linked to increased infection‐neutralization potential and therefore might indicate protective immunity. Using a prototype line assay based on the established recomLine SARS‐CoV‐2 assay, supplemented with RBD of the delta and the omicron variant, differential avidity determination of IgG directed towards RBD of wild‐type (WT) SARS‐CoV‐2 and distinct variants was possible within one assay. Our data confirm that natural SARS‐CoV‐2 infection or one vaccination step lead to low avidity IgG, whereas further vaccination steps gradually increase avidity to high values. High avidity is not reached by infection alone. After infection with WT SARS‐CoV‐2 or vaccination based on mRNA WT, the avidity of cross‐reacting IgG directed towards RBD of the delta variant only showed marginal differences compared to IgG directed towards RBD WT. In contrast, the avidity of IgG cross‐reacting with RBD of the omicron variant was always much lower than for IgG RBD WT, except after the third vaccination step. Therefore, parallel avidity testing of RBD WT and omicron seems to be mandatory for a significant assessment of protective immunity towards SARS‐CoV‐2. John Wiley and Sons Inc. 2022-07-26 2022-11 /pmc/articles/PMC9349558/ /pubmed/35851961 http://dx.doi.org/10.1002/jmv.28006 Text en © 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Bauer, Georg Struck, Friedhelm Staschik, Eva Maile, Julia Wochinz‐Richter, Karin Motz, Manfred Soutschek, Erwin Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title | Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title_full | Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title_fullStr | Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title_full_unstemmed | Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title_short | Differential avidity determination of IgG directed towards the receptor‐binding domain (RBD) of SARS‐CoV‐2 wild‐type and its variants in one assay: Rational tool for the assessment of protective immunity |
title_sort | differential avidity determination of igg directed towards the receptor‐binding domain (rbd) of sars‐cov‐2 wild‐type and its variants in one assay: rational tool for the assessment of protective immunity |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349558/ https://www.ncbi.nlm.nih.gov/pubmed/35851961 http://dx.doi.org/10.1002/jmv.28006 |
work_keys_str_mv | AT bauergeorg differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT struckfriedhelm differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT staschikeva differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT mailejulia differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT wochinzrichterkarin differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT motzmanfred differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity AT soutschekerwin differentialaviditydeterminationofiggdirectedtowardsthereceptorbindingdomainrbdofsarscov2wildtypeanditsvariantsinoneassayrationaltoolfortheassessmentofprotectiveimmunity |